This site is intended for health professionals only

Published on 2 July 2007

Share this story:
Twitter
LinkedIn

Genmab regains lymphoma drug rights

teaser

It is normally a sign of bad news but Genmab says it is delighted that Merck KGaA has returned the rights to a new lymphoma drug to the Denmark-based drugmaker.

Genmab has regained all rights to the HuMax-CD4



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn